
Opinion|Videos|October 28, 2024
Incorporating Real-World Evidence for HER2+ NSCLC
Key Takeaways
- Real-world evidence enhances understanding of HER2-directed therapies' effectiveness and safety in diverse populations, complementing clinical trial data.
- Collaboration among payers, providers, and manufacturers is vital for equitable access to HER2-directed therapies and cost management.
Panelists discuss how real-world evidence plays a crucial role in shaping both clinical decision-making and coverage policies for HER2-directed therapies in NSCLC, while exploring collaborative strategies between payers, providers, and manufacturers to balance equitable access with cost management.
Advertisement
Video content above is prompted by the following:
- What role do you see for real-world evidence in informing both clinical decision-making and coverage policies for HER2-directed therapies?
- (Heymach) How can collaboration between payers, providers, and manufacturers be leveraged to ensure equitable access to HER2-directed therapies while managing costs?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
4
Pricing and Insurance Networks in Outpatient Surgery Markets
5